ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

Study limitation reported by the research below: “No active comparator was used, so relative efficacy versus approved agents (semaglutide, tirzepatide) in this population cannot be determined from this trial.”

Papers